NCT05267626 - Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

April 4, 2022

Primary Completion Date

June 12, 2026

Study Completion Date

June 12, 2026

Conditions

Advanced Solid TumorMetastatic CancerCutaneous MelanomaNon-Small Cell Lung Cancer

Interventions

DRUG

AU-007

Monoclonal Antibody Targeting IL-2

DRUG

Aldesleukin

IL-2

DRUG

Avelumab

Monoclonal Antibody Targeting PD-L1

DRUG

Nivolumab

Monoclonal Antibody Targeting PD-1

Trial Locations (16)

2228

RECRUITING

Southside Cancer Care Centre, Miranda

3004

RECRUITING

The Alfred Hospital, Melbourne

3021

RECRUITING

Sunshine Hospital, Saint Albans

3084

RECRUITING

Austin Health, Heidelberg

3168

RECRUITING

Monash Health, Clayton

3199

RECRUITING

Peninsula & South Eastern Haematology and Oncology Group, Frankston

5042

RECRUITING

Southern Oncology Clinical Research Unit, Bedford Park

28078

RECRUITING

Carolina Biooncology Institute, Huntersville

78229

RECRUITING

START South Texas Accelerated Research Therapeutics, San Antonio

84112

RECRUITING

University of Utah - Huntsman Cancer Institute, Salt Lake City

49503-2563

RECRUITING

START Midwest, Grand Rapids

55404-4526

RECRUITING

Minnesota Oncology and Hematology PA, Minneapolis

63110-1010

RECRUITING

Washington University, St Louis

37203-1619

RECRUITING

Sarah Cannon Research Institute, Nashville

78731-4214

RECRUITING

Texas Oncology (Balcones) - SCRI, Austin

77030-4000

RECRUITING

MD Anderson Cancer Center, Houston